By screening a Food and Drug Administration (FDA)-approved compounds library, clemizole has been identified as efficient to improve the epileptic phenotype resulting from Nav1.1 haploinsufficiency on a zebrafish model for Dravet syndrome (Baraban et al., 2013). Here, SCN1A is linked to Dravet syndrome.